


 Cite this: *RSC Adv.*, 2021, 11, 7839

Inversion kinetics of some *E/Z* 3-(benzylidene)-2-oxo-indoline derivatives and their *in silico* CDK2 docking studies†‡

 Hany S. Mansour, Hend A. A. Abd El-wahab, Ahmed M. Ali and Tarek Aboul-Fadl *

The structure-based design of some CDK2 inhibitors with a 3-(benzylidene)indolin-2-one scaffold as potential anticancer agents was realized. Target compounds were obtained as *E/Z* mixtures and were resolved to corresponding *E*- and *Z*-diastereomers. *In silico* studies using MOE 2019.01 software revealed better docking on the targeted enzyme for the *Z*-diastereomer compared to the *E*-one. A time-dependent kinetic isomerization study was carried out for the inversion of *E/Z* diastereomers in DMSO- d_6 at room temperature, and were found to obey the first order kinetic reactions. Furthermore, a determination of the kinetic inter-conversion rate order by graphical analysis method and calculation of the rate constant and half-life of this kinetic process were carried out. For the prediction of the stability of the diastereomer(s), a good multiple regression equation was generated between the reaction rates of isomerization and some QM parameters with significant *p* value.

Received 19th December 2020

Accepted 1st February 2021

DOI: 10.1039/d0ra10672k

rsc.li/rsc-advances

Introduction

The 2-oxo-indoline scaffold is strongly associated with the anticancer activity through multiple targets as cyclin-dependent kinases (CDKs) and receptor tyrosine kinases (RTKs).^{1–4} Cyclin-dependent kinases (CDKs) are the key regulators of the cell cycle,^{5–8} the complex process by which cells divide. The recognition of the importance of CDKs to the process of cell division has stimulated an interest in them as potential targets for the management of cancer.^{9,10} Molecules having the 2-oxo-indoline scaffold usually compete with ATP for binding in the enzyme active site, and prevent phosphate transfer from ATP to the appropriate residue (Tyr, Ser, Thr). Thus, they block auto- and substrate phosphorylation, and therefore signal transduction and oncogenic activity.¹¹ The selectivity of these classes of compounds to the subclasses of CDKs and RTKs is determined by other interactions between substituents on the scaffold and residues found around this hinge region at the interaction site.^{12,13} 3-Arylidene-2-oxo-indoline derivatives are at the heart of a wide range of clinically, medicinally and biologically important compounds.^{14–17} A number of 3-arylidene-2-oxo-indolines have been approved for clinical application. Of particular significance is sunitinib, which is a clinically used receptor

tyrosine kinase (RTK) inhibitor for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumours,¹⁴ in addition to semaxanib, toceranib phosphate, and SU9516.^{11,14} They possess the capacity to bind the receptor tyrosine kinase (RTK), CDK2 enzyme and Aurora B with high affinity.¹⁴ Orantinib is a receptor tyrosine kinase inhibitor that was approved as an antiproliferating agent, and nintedanib is an inhibitor of PDGF, FGF and VEGF receptors and was approved for the treatment of non-small-cell lung cancer,^{18,19} Fig. 1.

It has been established for more than half a century that stereochemistry is fundamental in biological activities.^{20,21} The stereoselection, which has been extensively studied, was almost exclusively explained in terms of diastereoselective interactions for sunitinib and related compounds. Interestingly, these molecules were bound as the *Z*-diastereomer, even though they were the *E*-diastereomer in solution. The *E* form must be converted to the *Z* form before binding, as all *E*-diastereomers were inactive. Apparently, this conversion was shown to be mediated by acid, base or light.²² Removing such unsaturation and/or designing stereochemically stable compounds may be feasible, provided that activities are not compromised. This would avoid the issue of *E/Z* isomerization however, the vinyl proton was determined to be essential for activity.^{17,22}

Molecular modeling revealed that the oxindole moiety of sunitinib is crucial for binding to the ATP binding site of RTKs and CDKs.^{23,24} Additionally, the pyrrole functionality and the C(5)-F element of (2-oxoindolin-3-ylidene)methylpyrrole in the sunitinib structure both enhance affinity by inducing further hydrophobic interactions.^{19,20,22}

Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Assiut, Egypt. E-mail: fadl@aun.edu.eg

† Presented in 18th Austrian Chemistry Days, Linz – Austria, September 24 to 27, 2019.

‡ Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra10672k






Fig. 1 Clinically approved 2-oxo-indoline derivatives.




Fig. 2 General structure for 3-benzylidene-substituted oxindoles.

In contrast, the water-soluble diethyl amino ethyl tail of sunitinib lies on the protein surface. The RTK inhibitory activity and selectivity of (2-oxo-indolin-3-ylidene) methylpyrrole derivatives revealed strong relationships with structural modifications.²⁵

In view of the above facts, and in continuation of our interest in the synthesis and *in silico* investigation of the CDK activities of 2-oxo-indoline derivatives,²⁶ the current work describes the


synthesis of a series of some 3-benzylidene substituted oxindole derivatives (Fig. 2).

Recent studies have been made for its effective synthesis, and also for the stereoselective synthesis of (*E*) and (*Z*) diastereomers.^{27–31} Accordingly, the kinetics of the *E/Z* isomerization of the designed molecules seemed to be of interest.


Results and discussion

Chemistry

3-Benzylidenes **6(a–c)** were obtained using the Wolff–Kishner-like reduction of indolin-2,3-dione, **1** (isatin), with hydrazine hydrate, followed by reaction with an appropriate benzaldehyde.^{32,33} 5-Nitro derivatives **4(a–c)** were obtained by nitration at position 5 of the 2-oxo-indoline moiety with potassium nitrate in cold concentrated sulfuric acid.^{34,35} *N*-Substituted derivatives [**5(a–d)** and **7(a–b)**] were obtained by reacting [**4(a–c)** and **6(a–c)**]



Scheme 1 (a) NH₂NH₂·H₂O, reflux at 140 °C/4 h; (b) KNO₃/H₂SO₄, stir at 0–5 °C/1.5 h; (c) substituted benzaldehydes, piperidine, ethanol, reflux at 90 °C/4–5 h; (d) K₂CO₃/KI, DMF, alkyl halides/stir at 60–80 °C/4–12 h.

Table 1 *E* : *Z* diastereomeric ratios of the synthesized compounds 5(a–d), 6a, 6c and 7(a–b) and the yield (%)


Compd	Substituents			Chemical shifts (δ ppm)				Initial <i>E</i> : <i>Z</i> ratio	Yield (%)
	R ₁	R ₂	R ₃	vinyl H		2' and 6'-Hs			
				<i>E</i>	<i>Z</i>	<i>E</i>	<i>Z</i>		
5a	NO ₂	4'-F	Benzyl	8.02	8.38	7.91	8.60	6 : 94	67
5b	NO ₂	4'-F	Propyl	7.93	8.29	7.87	8.58	17 : 83	77
5c ₁	NO ₂	4'-OCH ₃	Propyl	7.86	8.19	7.78	8.56	30 : 70	45
5c ₂	NO ₂	4'-OCH ₃	Propyl	7.86	8.19	7.78	8.56	65 : 35	45
5d	NO ₂	2'-Cl	Propyl	7.87	8.30	7.71	8.06	93 : 7	62
6a	H	4'-Br	H	7.57	7.78	7.72	8.32	100 : 0	80
6c	H	4'-OCH ₃	H	7.59	7.75	7.72	8.48	98 : 2	75
7a	H	4'-F	Benzyl	7.8	7.96	7.83	8.54	18 : 82	67
7b ₁	H	4'-F	Propyl	7.7	7.89	7.79	8.51	2 : 98	55
7b ₂	H	4'-F	Propyl	7.7	7.89	7.79	8.51	88 : 12	55

with benzyl chloride or propyl bromide according to the reported procedures,^{26,27} Scheme 1.

All of the synthesized compounds 4(a–c), 5(a–d), 6(a–c) and 7(a–b) were obtained as mixtures of the *E* and *Z* diastereomers in different ratios, as identified with their vinyl-H and 2' and 6'-Hs chemical shifts (ppm) of *E* and *Z*, Table 1.

The configuration of the major diastereomer was confirmed by 2D NOE analysis, within the time of measurement. The *E*-configured compounds showed NOE between the proton at C4 and the protons at C-2' and C-6' (Fig. 3A), whereas the *Z*-configured compounds showed NOE between the proton at the C-4 and the vinyl proton (Fig. 3B).

The assignment of the *E/Z* diastereomers were confirmed by ¹H-NMR, where the vinyl protons resonated at a slight downfield shift in the *Z*-diastereomer compared to the *E*-diastereomer due to the influence of the 2-carbonyl group.

The *ortho*-benzylidene protons (H_{2',6'}) were found to be more shielded in the *E*-diastereomers for the same reason, as shown in Fig. 3. The ¹H NMR spectra of 5c is shown in Fig. 4 as a representative example. The chemical shifts of the major diastereomer (*Z*) revealed signals of H_{vinyl} at 8.25 ppm, H₄ at 8.72 ppm and H_{2',6'} at 8.59 ppm, while those of the minor diastereomer (*E*) resonated at 7.9, 8.52 and 7.82 ppm, respectively.

The configuration of the *E/Z* diastereomers of 5c was further confirmed by the NOESY 2D-¹H NMR. The NOE interaction between H_{vinyl} and H₄ was shown in the *Z*-diastereomer, Fig. 5A, while the NOE interaction between H_{2',6'} and H₄ was shown in the *E*-diastereomer, Fig. 5B.

Kinetics of the isomerization study

It has been reported that the *E/Z* diastereomers of 3-benzylidene-2-oxo-indolines both can undergo isomerization to




Fig. 3 General configuration of *E* and *Z* diastereomers. (A) NOE interaction between H_{2',6'} and H₄ in *E*-diastereomer. (B) NOE interaction between vinyl-H and H₄ in *Z*-diastereomer.




Fig. 4 ^1H -NMR chart (aromatic region) of compound 5c_1 , mixture of the E/Z diastereomers with a ratio = 35 : 65.

each other.^{28,29} This phenomenon is also observed in the change of the initial $E : Z$ product ratios for the synthesized compounds listed in Table 1 during the measurement of the ^1H NMR spectra in DMSO-d_6 . To acquire knowledge on the rates of the configurational isomerization of the E/Z diastereomers for compounds 5a , 5b , 5c_1 , 5c_2 , 5d , 6a , 6c , 7a , 7b_1 and 7b_2 , the change of the initial diastereomeric ratios at time intervals was measured in DMSO-d_6 at room temperature, and are listed in Table 2.

The diastereomeric ratios of the tested compounds were monitored using ^1H NMR by measuring the integral height values of the vinyl and $2',6'$ -protons of the respective E and Z diastereomers. With the exception of compounds 5b , 5c_1 and 7b_2 that revealed no or insignificant isomerization at the reaction conditions, the rate of the isomerization reactions of the other tested compounds were found to display first-order kinetics over the investigated solvent and





Fig. 5 NOESY ^1H - ^1H 2D NMR interactions of the E/Z -diastereomers of 5c . (A) The major diastereomer (Z). (B) The minor diastereomer (E).

Table 2 Time-dependent isomerization of *E* and *Z* diastereomers in DMSO-*d*₆

Compd	Substituents			<i>E</i> : <i>Z</i> ratio	<i>E</i> : <i>Z</i> ratio	<i>E</i> : <i>Z</i> ratio	<i>E</i> : <i>Z</i> ratio	<i>E</i> : <i>Z</i> ratio	Isomerization
	R ₁	R ₂	R ₃	Time: 0 h	1 h	2 h	3 h	5 h	
5a	NO ₂	4'-F	Benzyl	5.7 : 94.3	8.3 : 91.7	12.3 : 87.7	13.0 : 87.0	17.4 : 82.6	From <i>Z</i> to <i>E</i>
5b	NO ₂	4'-F	Propyl	17 : 83	17 : 83	17 : 83	17 : 83	17 : 83	No isomeriz.
5c ₁	NO ₂	4'-OCH ₃	Propyl	30.1 : 69.9	34.6 : 65.4	33.8 : 66.2	35.1 : 64.9	35.1 : 64.9	From <i>Z</i> to <i>E</i>
5c ₂	NO ₂	4'-OCH ₃	Propyl	64.9 : 35.1	61.3 : 38.7	55.2 : 44.8	51.3 : 48.7	44.4 : 55.6	From <i>E</i> to <i>Z</i>
5d	NO ₂	2'-Cl	Propyl	92.6 : 7.4	88.5 : 11.5	84.0 : 16.0	82.0 : 18.0	80.6 : 19.4	From <i>E</i> to <i>Z</i>
6a	H	4'-Br	H	100 : 0	96.2 : 3.8	94.3 : 5.7	91.7 : 8.3	90.1 : 9.9	From <i>E</i> to <i>Z</i>
6c	H	4'-OCH ₃	H	98.0 : 2.0	96.2 : 3.8	93.5 : 6.5	91.7 : 8.3	90.1 : 9.9	From <i>E</i> to <i>Z</i>
7a	H	4'-F	Benzyl	18.0 : 82.0	30.1 : 69.9	35.1 : 64.9	38.3 : 61.7	42.9 : 57.1	From <i>Z</i> to <i>E</i>
7b ₁	H	4'-F	Propyl	2.0 : 98.0	13.0 : 87.0	15.3 : 84.7	20.6 : 79.4	29.1 : 70.9	From <i>Z</i> to <i>E</i>
7b ₂	H	4'-F	Propyl	87.7 : 12.3	87.0 : 13.0	87.0 : 13.0	87.0 : 13.0	87.0 : 13.0	From <i>E</i> to <i>Z</i>

Fig. 6 Graphical representation of first-order kinetic isomerization of the *E/Z* diastereomers for representative compounds 5c₂ and 5d.

temperature. Representative first-order kinetics plots for the isomerization of the tested compounds are shown in Fig. 6. From the slopes of the linear correlations, it can be seen that the potential for isomerization proceeds with varied rates, and the rate data obtained for the tested compounds are recorded in Table 3.

No general behavior pattern for the isomerization of the tested compounds was observed. Compounds 5b and 5c showed no significant *Z/E* isomerization, but the rate of *E/Z* isomerization of 5c ($t_{1/2} = 8.3$ h) revealed more stability for the *Z* isomer. On the other hand, compound 7b showed no *E/Z* isomerization, but the rate of *Z/E* isomerization ($t_{1/2} = 12.53$ h) revealed that the *E* diastereomer is more stable. Attempts to carry out additional studies on these

compounds using other solvents, such as CDCl₃, failed due to solubility issues. No attempts were made to investigate the mechanism of isomerization; however, this observed phenomenon is consistent with previously reported ones.^{28,29,36,37}

Molecular structure and modeling studies

Molecular orbital calculations were carried out to investigate the structure and stability of the *E/Z*-diastereomers of the subjected molecules. The investigated benzylidene oxindole structures were optimized in the ground state using AM1 and PM3, and MNDO semi-empirical methods with default Hartree-Fock (RHF) basis using MOE 2019.01 software.

To determine which diastereomer is more stable (*E* or *Z*), the heat of formation (HF, kcal mol⁻¹) was calculated for each diastereomer by three different methods, AM1, MNDO and PM3. The results are recorded in Table 4.

From the results recorded in Table 4, the AM1 Hamiltonian shows that the (*E*) diastereomers are more stable than (*Z*) diastereomers for compounds 5a, 5b, 6a, 7a and 7b. However, the (*Z*) diastereomers are more stable than (*E*) diastereomers for compounds 5c, 5d and 6c. This is consistent with the observed rate of isomerization of the tested compounds (5c₂ and 7b₁ compared to the other tested compounds). The MNDO model showed that the (*Z*) diastereomers are slightly more stable, while the PM3 model

Table 3 Rate data for the isomerization of the tested compounds in DMSO-*d*₆ at room temperature

Compd	$k \times 10^3$ (min ⁻¹) (r^2 , r)	$t_{1/2}$ (h)
5a	0.461 (0.969, 0.984)	25.08
5c ₂	1.382 (0.995, 0.997)	8.37
5d	0.461 (0.878, 0.937)	25.08
6a	0.230 (0.930, 0.964)	50.15
6c	0.230 (0.951, 0.975)	50.15
7a	0.415 (0.996, 0.998)	27.85
7b ₁	0.921 (0.969, 0.984)	12.53

Table 4 Heat of formation, total energy and potential energy calculated for the *E/Z* diastereomers of the 3-benzylidene-2-oxo-indoline derivatives by quantum mechanics (QM) methods

Compd and config.	Heat of formation (kcal mol ⁻¹)			Total energy (kcal mol ⁻¹)			Potential energy (kcal mol ⁻¹)			
	AM1	MNDO	PM3	AM1	MNDO	PM3	AM1	MNDO	PM3	
5a	<i>E</i>	37.256	31.578	11.693	-112 488.86	-112 511.38	-103 287	93.276	89.752	94.042
	<i>Z</i>	37.340	30.934	6.627	-112 488.77	-112 512.03	-103 286.73	95.959	92.903	96.041
5b	<i>E</i>	-1.852	-7.613	-21.439	-100 700.08	-100 751.77	-92 381.56	77.165	72.529	84.174
	<i>Z</i>	-1.635	-8.351	-31.127	-100 699.96	-100 752.5	-92 380.82	80.214	75.271	85.692
5c	<i>E</i>	5.382	-0.8790	-26.998	-100 804.24	-101 053.02	-92 797.19	92.313	91.605	92.963
	<i>Z</i>	4.534	-1.486	-25.804	-100 803.59	-101 053.63	-92 795.82	94.633	93.192	95.918
5d	<i>E</i>	37.420	32.169	5.746	-98 132.34	-97 872.59	-89 533.23	80.254	73.658	88.894
	<i>Z</i>	37.414	31.458	10.397	-98 132.13	-97 873.28	-89 532.20	85.874	77.747	90.804
6a	<i>E</i>	52.500	33.937	40.929	-67 732.13	-67 673.79	-63 169.75	59.044	60.917	64.915
	<i>Z</i>	52.959	33.491	41.925	-67 731.67	-67 674.24	-63 168.77	60.866	61.366	65.561
6c	<i>E</i>	9.479	-8.195	-4.928	-70 874.54	-71 014.01	-65 587.71	69.970	72.328	74.772
	<i>Z</i>	9.435	-8.622	-3.910	-70 874.59	-71 014.44	-65 586.70	71.709	73.687	75.343
7a	<i>E</i>	33.941	25.706	15.403	-93 328.44	-93 289.73	-86 419.95	86.114	79.532	97.061
	<i>Z</i>	41.257	15.488	21.588	-93 326.40	-93 290.25	-86 418.98	89.310	80.142	97.613
7b	<i>E</i>	-4.797	-22.279	-22.610	-81 539.30	-81 529.20	-75 514.30	65.373	62.142	79.378
	<i>Z</i>	-3.140	-22.891	-21.660	-81 537.63	-81 529.82	-75 513.34	67.784	62.867	81.496

Table 5 Modeling and QM calculations variables of the optimized structures^a

Compd	<i>t</i> _{1/2} (h)	Heat of formation	Dipole moment	Electrostatic energy	Strain energy	vdW energy	Topological polar surface area	vdW area	Electrostatic interaction energy	Torsion energy
		AM1_H	AM1_dipole	E_ele	E_strain	E_vdW	TPSA	vdW_area	E_rele	E_tor
5c	8.37	5.382	2.939	-1.068	15.948	7.525	75.360	335.918	20 118.777	0.914
5d	25.08	37.420	3.400	9.667	14.098	5.785	66.130	321.263	19 081.748	-0.052
6a	50.15	52.500	2.349	-13.894	10.470	4.959	29.100	243.157	10 623.542	7.366
6c	50.15	9.479	3.308	-18.750	12.762	6.472	38.330	246.036	11 923.694	7.411
5a	25.08	37.340	3.895	7.004	15.010	9.655	66.130	344.125	21 515.154	4.774
7a	27.85	41.257	3.532	0.3197	14.470	7.020	20.310	315.987	12 584.364	5.612
7b	12.53	-3.140	3.621	-1.1060	12.974	4.445	20.310	279.953	10 202.203	0.011

^a AM1_H: heat of formation, AM1_dipole: dipole moment, E_ele: electrostatic energy, E_strain: strain energy, E_vdW: vdW energy, TPSA: topological polar surface area, vdW_area: vdW area, E_rele: electrostatic interaction energy, E_tor: torsion energy.

Table 6 The correlation matrix of *t*_{1/2} of the *E/Z* isomerization with modeling and QM calculation variables of the optimized structures

Variable	<i>t</i> _{1/2} (<i>E/Z</i>)	AM1_H	AM1_dipole	E_ele	E_strain	E_vdW	TPSA	vdW_area	E_rele	E_tor
<i>t</i> _{1/2}	1.000									
AM1_H	0.632	1.000								
AM1_dipole	-0.211	0.200	1.000							
E_ele	-0.736	0.000	0.400	1.000						
E_strain	-0.949 ^a	0.800	0.400	0.600	1.000					
E_vdW	0.632	-1.000	0.200	0.000	0.800	1.000				
TPSA	-0.949 ^a	0.800	0.400	0.600	1.000	0.800	1.000			
vdW_area	-0.949 ^a	0.800	0.400	0.600	1.000	0.800	1.000	1.000		
E_rele	-0.948 ^a	0.800	0.400	0.600	1.000	0.000	1.000	1.000	1.000	
E_tor	0.738	0.000	-0.400	-1.000	-0.600	-1.000	-0.600	-0.600	-0.600	1.000

^a Significant *p* value (0.05).

Table 7 Estimated and found $t_{1/2}$ values, and their corresponding significant QM parameters

Compd	Estimated $t_{1/2}$ (h)	Found $t_{1/2}$ (h)
5c ₂	7.57	8.37
5d	21.33	25.08
6a	47.27	50.15
6c	49.32	50.15
5a	30.67	25.08
7a	19.72	27.85
7b ₁	23.32	12.53
5b	34.36	ND ^a
5c ₁	7.57	ND
7b ₂	23.32	ND

^a Not Determined.

revealed that the (*E*) diastereomers are more stable, except for compounds 5a and 5b.

In order to disclose this inconsistency between the three methods and the additional calculations of the total energy and potential energy of each diastereomer, these calculations were also computed by three different methods (AM1, MNDO and PM3), and the results are recorded in Table 4. According to the total energy calculations, the (*E*) diastereomers are more stable than the (*Z*) diastereomers according to AM1 and PM3 for all compounds except compound 6c, as the AM1 calculations reveal that the (*Z*) diastereomer is slightly more stable. The MNDO calculations for the total energy still shows that the (*Z*) diastereomers are slightly more stable than the (*E*) diastereomer. However, based on the potential energy calculations by the three methods (AM1, MNDO and PM3), it is clear that the (*E*) diastereomers are more stable than (*Z*) isomers for all compounds.

In conclusion, the AM1 method has shown better performance compared to PM3 and MNDO methods for the molecular

geometry optimization of the investigated 3-benzylidene oxindole molecules.

For a better understanding of the factors affecting the rate of *E/Z* or *Z/E* isomerization, the Spearman correlation (2-tailed) was studied between $t_{1/2}$ and 9 selected physicochemical parameters, Table 5. Data were recorded and analyzed with IBM SPSS V22, and the *P*-value was considered significant if it was equal to or less than 0.05.

Accordingly, the cross correlation coefficient between $t_{1/2}$ (*E/Z* isomerization) and *E_strain*, *TPSA*, *vdW_area* and electrostatic interaction energy was high (0.949) with a significant *p* value (0.05), Table 6. However, when studying the cross correlation between $t_{1/2}$ (*Z/E* isomerization), no significant correlation was obtained between the $t_{1/2}$ (*Z/E* isomerization) and calculated descriptors.

A good multiple regression equation was generated between the half-life ($t_{1/2}$) of the isomerization and the QM parameters with significant *p* value, eqn (1): multiple regression equation between $t_{1/2}$ and significant QM parameters.

$$t_{1/2} = 187.5378 + 1.542499 \times E_strain - 1.63343 \times TPSA - 1.0012 \times vdW_area + 0.012667 \times E_rele, \\ n = 7, R^2 = 0.8536 \quad (1)$$

The isomerization rate and stability of the diastereomers can be estimated using this equation. Matching the experimental data with the estimated ones, Table 7 and Fig. 7, revealed a quite good relationship.

Molecular docking study on CDK2

The molecular docking study was performed to predict the binding and effect of the investigated molecules on the CDK2 enzyme, and the results are recorded in Table 8. As a general pattern, it is clear from the obtained data that the *Z*-diastereomers revealed better binding affinity to the active site of CDK2. In most of the tested compounds, the binding scores are quite close to that of the reference drug sunitinib [redocking rmsd of sunitinib = 2]. Further computational studies together with biological activity are




Fig. 7 Correlation between found $t_{1/2}$ and estimated $t_{1/2}$.

Table 8 The scores of the docked ligands

Compd	Score (S, kcal mol ⁻¹)	Compd	Score (S, kcal mol ⁻¹)
Sunitinib	-7.8956		
5a-E	-7.8976	5a-Z	-8.0125
5b-E	-7.3031	5b-Z	-7.2988
5c-E	-7.5347	5c-Z	-7.1837
5d-E	-6.7651	5d-Z	-7.1422
6a-E	-6.3125	6a-Z	-6.6100
6c-E	-6.3683	6c-Z	-6.7596
7a-E	-6.5126	7a-Z	-7.7525
7b-E	-6.9255	7b-Z	-6.8315

currently in progress. Fig. 8 illustrates the 2D and 3D interactions of the co-crystallized sunitinib, the Z-diastereomer of 5a, and the E-diastereomer 6c.

Conclusion

A series of 3-benzylideneindolin-2-ones and 5-nitro 3-benzylidene indolin-2-ones have been synthesized and obtained as *E/Z*-diastereomers. The compounds have been assigned as *Z* or *E* configurations by ¹H NMR analysis. The configuration of the separated *E*- and *Z*-diastereomers were confirmed by 2D NOE. A kinetic study of the *E/Z* isomerization was carried out in DMSO-d₆ at room temperature, and they were found to obey first-order kinetic reactions. To justify the stability of (*E*) or (*Z*), the heat of formation (HF, kcal mol⁻¹) was calculated for each diastereomer by three different methods, AM1, MNDO and PM3. No clear justification could be obtained; however, the AM1 method has shown better performance compared to PM3 and MNDO. Furthermore, a good multiple regression equation was generated between the reaction rates of isomerization and some QM parameters with significant *p* value for prediction of stability of




Fig. 8 2D and 3D ligand interactions of (A) co-crystallized sunitinib (Z) with CDK2, (B) 5a (Z-diastereomer), (C) compound 6c (E-diastereomer). All ligands are docked into the active site of CDK2 (PDB ID: 3T11).

the diastereomer(s). *In silico* docking studies using MOE 2019.01 software revealed better docking on the targeted CDK2 enzyme for the *Z*-diastereomer compared to the *E*-one, and comparable docking scores to sunitinib as a reference drug.

Experimental section

Chemicals were obtained commercially, and were used as received. TLC was carried out on Merck 0.2 mm pre-coated silica gel (60 F-254) aluminum sheets. The spots were visualized by UV. Synthesized compounds were purified by column chromatography using methanol/CH₂Cl₂ as the mobile phase. Melting points were measured with a capillary melting point SMP1 apparatus (Stuart Scientific), and are uncorrected. ¹H and ¹³C NMR spectra were recorded on a Bruker-400 MHz at the NMR unit, Faculty of Pharmacy El-Mansoura University, El-Mansoura, Egypt. The chemical shifts are expressed in parts per million (δ) downfield relative to tetramethylsilane as an internal standard (0 ppm). Coupling constants are reported in hertz (Hz). Elemental analyses were performed on a Perkin Elmer 2400 CHN elemental analyzer at the Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt.

All calculations based on semi-empirical molecular orbital theory have been carried out using Molecular Operating Environment (MOE 2019.01, 2019; Chemical Computing Group, Canada) software at the Medicinal Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.

Synthesis of indolin-2-one (oxindole) (2)

A stirred solution of isatin **1** (0.01 mol; 1.47 g) in hydrazine hydrate (15 ml) was heated to 140 °C for 4 h. The reaction was cooled to room temperature, poured into ice-cold water, then acidified to pH 2 with 6 N hydrochloric acid and kept at room temperature for 2 days. The solution was extracted with CH₂Cl₂ (5 × 20), dried over anhydrous sodium sulfate, filtered, and then re-crystallized from water to give the pure compound. Yield = 80% (1.18 g), mp: 126–128 °C (lit.,³⁸ 127–129 °C).

¹H-NMR (DMSO-d₆, 60 MHz) δ :

9.15 (bs, 1H, NH), 7.4–6.7 (m, 5H, H_{4,5,6,7}), 3.48 (s, 2H, H_{3,3}) ppm.

Synthesis of 5-nitroindolin-2-one (3)

To a stirred solution of 2-oxo-indoline **2** (30 mol; 4 g) in cold concentrated sulfuric acid at 0 °C (28 ml), a cold solution of potassium nitrate (30 mmol; 3.87 g) in concentrated sulfuric acid (28 ml) was added in one portion. Stirring was continued for 1.5 h in an ice bath (the temperature of the mixture must not exceed 5 °C), and the mixture was then added to 250 ml of crushed ice. The buffy-colored precipitate was collected by filtration, washed with water, and dried. The raw product was purified by recrystallization from acetic acid (50%) to give the pure product. Yield: 70% (3.75 g), mp: 247–250 °C (lit.,³⁴ 249–254 °C).

¹H-NMR (DMSO-d₆, 60 MHz) δ :

11.25 (bs, 1H, NH), 8.3–8 (m, 2H, H_{4,6}), 7.01 (d, *J* = 7.7 Hz, 1H, H₇), 3.66 (s, 2H, H_{3,3}) ppm.

General procedure for the synthesis of target compounds (6a and 6c) as reported^{33,39}

Piperidine (0.01 mmol) was added to a solution of compound **2** or **3** (10 mmol) and appropriate substituted benzaldehyde (11 mmol) in ethanol (15 ml). The mixture was refluxed for 3–5 h, and then the reaction mixture was cooled to room temperature and left overnight. The precipitate was filtered, washed with ethanol, and dried at room temperature to give the titled compounds. The obtained crude products were purified by column chromatography.

(*E/Z*)-3-(4-Bromobenzylidene)indolin-2-one (**6a**).³⁶ Orange-yellow solid crystals; yield: 80%; mp: 193–195 °C;

IR: 3472 and 1708.2 cm⁻¹.

¹H-NMR (DMSO-d₆, 400 MHz) δ :

E-Diastereomer: 10.65 (s, 1H, NH), 7.72 (d, *J* = 8.3 Hz, 2H, H_{2',6'}), 7.66 (d, *J* = 8.3 Hz, 2H, H_{3',5'}), 7.57 (s, 1H, =CH-), 7.49 (d, *J* = 7.7 Hz, 1H, H₄), 7.24 (t, *J* = 7.7 Hz, 1H, H₅), 6.87 (m, 2H, H_{6,7}) ppm.

Z-Diastereomer: 10.69 (s, 1H, NH), 8.32 (d, *J* = 8.3 Hz, 2H, H_{2',6'}), 7.78 (s, 1H, =CH-), 7.71 (m, 1H, H₄), 7.68 (m, 2H, H_{3',5'}), 7.22 (t, *J* = 7.7 Hz, 1H, H₅), 6.99 (t, *J* = 7.7 Hz, 1H, H₆), 6.82 (m, 1H, H₇) ppm.

(*E/Z*)-3-(4-Methoxybenzylidene)indolin-2-one (**6c**).³⁶ Bright yellow solid crystals; yield: 75%; mp: 160–162 °C;

IR: 3452.5 and 1703.5 cm⁻¹.

¹H-NMR (DMSO-d₆, 400 MHz) δ :

E-Diastereomer: 10.58 (s, 1H, NH), 7.72 (d, *J* = 8.5, 2H, H_{2',6'}), 7.66 (d, *J* = 7.8 Hz, 1H, H₄), 7.59 (s, 1H, =CH-), 7.22 (t, *J* = 7.7 Hz, 1H, H₅), 7.09 (d, *J* = 8.5 Hz, 2H, H_{3',5'}), 6.87 (m, 2H, H_{6,7}), 3.84 (s, 3H, -OCH₃) ppm.

Z-Diastereomer: 10.61 (s, 1H, NH), 8.48 (d, *J* = 8.5, 2H, H_{2',6'}), 7.75 (s, 1H, =CH-), 7.66 (d, *J* = 7.8 Hz, 1H, H₄), 7.18 (t, *J* = 7.7 Hz, 1H, H₅), 7.04 (d, *J* = 8.5 Hz, 2H, H_{3',5'}), 6.98 (t, *J* = 7.7 Hz, 1H, H₆), 6.82 (d, *J* = 8.0 Hz, 1H, H₇), 3.84 (s, 3H, -OCH₃) ppm.

General procedure for the synthesis of target compounds [5(a–d) & 7(a–b)]

The appropriate compound [4(a–c) and 6(a–c)] (10 mmol.) was dissolved in anhydrous DMF (5–10 ml), and cooled on ice with stirring. Solid K₂CO₃ (12 mmol) was added in one portion, and the dark colored suspension was brought to room temperature and stirred for an additional 1 h. Alkyl chloride or bromide (11 mmol) and KI (2 mmol) were added, and the reaction mixture was stirred at 60–80 °C for 5–24 h, until the starting material had been consumed (monitored by TLC). The reaction mixture was poured into HCl (0.5 M, 50 ml) and extracted with ethyl acetate (2 × 25 ml). The ethyl acetate portion was washed with brine and dried over anhydrous Na₂SO₄. The crude product was purified by column chromatography using CH₂Cl₂.

(*E/Z*)-3-(4-Fluorobenzylidene)-1-benzyl-5-nitroindolin-2-one (**5a**). *E* : *Z* ratio = 6 : 94.

Yellow solid powder; yield: 67%; mp: 218–221 °C;

¹H-NMR (DMSO-d₆, 400 MHz) δ :

Z-Diastereomer: 8.77 (d, *J* = 2.2 Hz, 1H, H₄), 8.60 (dd, *J* = 8.9, 1.8 Hz, 2H, H_{2',6'}), 8.38 (s, 1H, =CH-), 8.20 (dd, *J* = 8.7, 1.8 Hz,

1H, **H**₆), 7.43–7.23 (m, 7H, benzylic Hs, **H**_{3',5'}), 7.20 (d, *J* = 9.4 Hz, 1H, **H**₇), 5.09 (s, 2H, –**CH**₂–) ppm.

E-Diastereomer: 8.34 (d, *J* = 2.2 Hz, 1H, **H**₄), 8.22 (dd, *J* = 8.7, 2.2 Hz, 1H, **H**₆), 8.02 (s, 1H, =**CH**–), 7.91 (dd, *J* = 8.9, 1.8 Hz, 2H, **H**_{2',6'}), 7.47–7.25 (m, 7H, benzylic Hs, **H**_{3',5'}), 7.22 (d, *J* = 9.4 Hz, 1H, **H**₇), 5.10 (s, 2H, –**CH**₂–) ppm.

¹³C-NMR (DMSO-*d*₆, 100 MHz) δ:

Z-Diastereomer: 166.2, 165.5, 146.3, 143.1, 140.9, 136.5, 136, 135.9, 130.7, 129.2 (2C), 128, 127.8 (2C), 125.6, 123, 117.6, 116.2, 116, 115.9, 109.5, 43.6 ppm.

E-Diastereomer: 168.1, 162.9, 148.6, 142.6, 140.1, 136.2, 132.8, 132.7, 130.6, 129.3 (2C), 128.1, 127.7 (2C), 126.9, 125.2, 123.1, 121.1, 116.7, 116.5, 110, 43.5 ppm.

Elemental analysis calculated/found for C₂₂H₁₅FN₂O₃: C 70.58/70.41; H 4.04/4.23; N 7.48/7.29.

(*E/Z*)-1-Propyl-3-(4'-fluorobenzylidene)-5-nitro indolin-2-one (5b). *E* : *Z* ratio = 17 : 83.

Bright yellow solid powder; yield: 77%; mp: 177–180 °C;

¹H-NMR (DMSO-*d*₆, 400 MHz) δ:

Z-Diastereomer: 8.72 (d, *J* = 2.2 Hz, 1H, **H**₄), 8.58 (dd, *J* = 8.8, 1.8 Hz, 2H, **H**_{2',6'}), 8.29 (s, 1H, =**CH**–), 8.23 (dd, *J* = 1.8, 8.8 Hz, 1H, **H**₆), 7.37 (t, *J* = 9.2 Hz, 2H, **H**_{3',5'}), 7.31 (d, *J* = 9.2 Hz, 1H, **H**₇), 3.80 (t, 2H, –**CH**₂–CH₂–CH₃), 1.65 (m, 2H, –CH₂–**CH**₂–CH₃), 0.89 (t, 3H, –CH₂–CH₂–**CH**₃) ppm.

E-Diastereomer: 8.68 (d, *J* = 2.2 Hz, 1H, **H**₄), 8.37 (dd, *J* = 1.8, 8.8 Hz, 1H, **H**₆), 7.93 (s, 1H, =**CH**–), 7.87 (dd, *J* = 8.8, 1.8 Hz, 2H, **H**_{2',6'}), 7.53 (d, *J* = 8.9 Hz, 1H, **H**₇), 7.44 (t, *J* = 9.2 Hz, 2H, **H**_{3',5'}), 3.80 (t, 2H, –**CH**₂–CH₂–CH₃), 1.65 (m, 2H, –CH₂–**CH**₂–CH₃), 0.89 (t, 3H, –CH₂–CH₂–**CH**₃) ppm.

¹³C-NMR (DMSO-*d*₆, 100 MHz) δ:

Z-Diastereomer: 167.9, 166.1, 146.8, 142.8, 140.3, 135.9, 135.8, 130.8, 125.7, 123.3, 117.5, 116.1, 115.9, 115.8, 109.1, 41.7, 21, 11.5 ppm.

E-Diastereomer: 165.4, 162.9, 149.1, 142.3, 139.5, 132.7, 132.6, 130.6, 126.8, 125.1, 123.3, 117.5, 116.7, 116.5, 109.7, 41.8, 20.8, 11.6 ppm.

Elemental analysis calculated/found for C₁₈H₁₅FN₂O₃: C 66.25/66.47; H 4.63/4.75; N 8.58/8.8.

(*E/Z*)-3-(4-Methoxybenzylidene)-1-propyl-5-nitroindolin-2-one (5c₁). *E* : *Z* ratio = 30 : 70.

Yellow solid powder; yield: 45%; mp: 150–153 °C;

¹H-NMR (DMSO-*d*₆, 400 MHz) δ:

Z-Diastereomer: 8.67 (d, *J* = 1.3 Hz, 1H, **H**₄), 8.56 (d, *J* = 8.9, 2H, **H**_{2',6'}), 8.19 (s, 1H, =**CH**–), 8.17 (dd, *J* = 8.7 Hz, 2.2 Hz, 1H, **H**₆), 7.25 (d, *J* = 8.8 Hz, 1H, **H**₇), 7.06 (d, *J* = 8.9 Hz, 2H, **H**_{3',5'}), 3.86 (s, 3H, –O**CH**₃), 3.78 (t, 2H, –**CH**₂–CH₂–CH₃), 1.63 (m, 2H, –CH₂–**CH**₂–CH₃), 0.89 (t, 3H, –CH₂–CH₂–**CH**₃) ppm.

E-Diastereomer: 8.47 (d, *J* = 1.3 Hz, 1H, **H**₄), 8.21 (dd, *J* = 8.7 Hz, 2.2 Hz, 1H, **H**₆), 7.86 (s, 1H, =**CH**–), 7.78 (d, *J* = 8.8, 2H, **H**_{2',6'}), 7.31 (d, *J* = 8.8 Hz, 1H, **H**₇), 7.13 (d, *J* = 8.9 Hz, 2H, **H**_{3',5'}), 3.87 (s, 3H, –O**CH**₃), 3.78 (t, 2H, –**CH**₂–CH₂–CH₃), 1.63 (m, 2H, –CH₂–**CH**₂–CH₃), 0.89 (t, 3H, –CH₂–CH₂–**CH**₃) ppm.

¹³C-NMR (DMSO-*d*₆, 100 MHz) δ:

Z-Diastereomer: 166.3, 162.6, 146.2, 142.7, 141.6, 135.8 (2C), 127, 125.6, 124.8, 120.7, 115.1, 114.4 (2C), 108.8, 56, 41.6, 21.1, 11.6 ppm.

E-Diastereomer: 168.3, 161.9, 148.7, 142.2, 140.8, 132.6 (2C), 126.3, 126.2, 122.8, 121.3, 117.2, 114.9 (2C), 109.4, 56, 41.7, 21, 11.6 ppm.

Elemental analysis calculated/found for C₁₉H₁₈N₂O₄: C 67.44/67.71; H 5.36/5.49; N 8.28/8.57.

(*E/Z*)-3-(4-Methoxybenzylidene)-1-propyl-5-nitroindolin-2-one (5c₂). *E* : *Z* ratio = 65 : 35.

Yellow solid powder; yield: 77%; mp: 147–150 °C;

¹H-NMR (DMSO-*d*₆, 400 MHz) δ:

E-Diastereomer: 8.47 (d, *J* = 1.3 Hz, 1H, **H**₄), 8.21 (dd, *J* = 8.7 Hz, 2.2 Hz, 1H, **H**₆), 7.86 (s, 1H, =**CH**–), 7.78 (d, *J* = 8.8, 2H, **H**_{2',6'}), 7.33 (d, *J* = 8.8 Hz, 1H, **H**₇), 7.14 (d, *J* = 8.9 Hz, 2H, **H**_{3',5'}), 3.88 (s, 3H, –O**CH**₃), 3.79 (t, 2H, –**CH**₂–CH₂–CH₃), 1.63 (m, 2H, –CH₂–**CH**₂–CH₃), 0.90 (t, 3H, –CH₂–CH₂–**CH**₃) ppm.

Z-Diastereomer: 8.68 (d, *J* = 1.3 Hz, 1H, **H**₄), 8.57 (d, *J* = 8.9, 2H, **H**_{2',6'}), 8.19 (s, 1H, =**CH**–), 8.18 (dd, *J* = 8.7 Hz, 2.2 Hz, 1H, **H**₆), 7.27 (d, *J* = 8.8 Hz, 1H, **H**₇), 7.08 (d, *J* = 8.9 Hz, 2H, **H**_{3',5'}), 3.88 (s, 3H, –O**CH**₃), 3.79 (t, 2H, –**CH**₂–CH₂–CH₃), 1.63 (m, 2H, –CH₂–**CH**₂–CH₃), 0.90 (t, 3H, –CH₂–CH₂–**CH**₃) ppm.

¹³C-NMR (DMSO-*d*₆, 100 MHz) δ:

E-Diastereomer: 168.3, 161.9, 148.7, 142.2, 140.8, 132.6 (2C), 126.3, 126.2, 122.8, 121.3, 117.2, 114.9 (2C), 109.4, 56, 41.7, 21, 11.6 ppm.

Z-Diastereomer: 166.3, 162.6, 146.2, 142.7, 141.6, 135.8 (2C), 127, 125.6, 124.8, 120.7, 115.1, 114.4 (2C), 108.8, 56, 41.6, 21.1, 11.6 ppm.

Elemental analysis calculated/found for C₁₉H₁₈N₂O₄: C 67.44/67.71; H 5.36/5.49; N 8.28/8.57.

(*E/Z*)-3-(2-Chlorobenzylidene)-1-propyl-5-nitroindolin-2-one (5d). *E* : *Z* ratio = 93 : 7.

Yellow solid powder; yield: 62%; mp: 136–139 °C;

¹H-NMR (DMSO-*d*₆, 400 MHz) δ:

E-Diastereomer: 8.25 (dd, *J* = 7.8, 2.2 Hz, 1H, **H**₆), 7.97 (d, *J* = 2.2 Hz, 1H, **H**₄), 7.87 (s, 1H, =**CH**–), 7.85 (d, *J* = 7.8 Hz, 1H, **H**_{3'}), 7.71 (d, *J* = 8.8 Hz, 1.1 Hz, 1H, **H**_{6'}), 7.62 (td, *J* = 7.5 Hz, 0.8 Hz, 1H, **H**_{4'}), 7.55 (t, *J* = 2.4 Hz, 1H, **H**_{5'}), 7.38 (d, *J* = 8.8 Hz, 1H, **H**₇), 3.80 (t, *J* = 2.4 Hz, 2H, –**CH**₂–CH₂–CH₃), 1.65 (m, 2H, –CH₂–**CH**₂–CH₃), 0.91 (t, *J* = 2.4 Hz, 3H, –CH₂–CH₂–**CH**₃) ppm.

Z-Diastereomer: 8.76 (d, *J* = 2.2 Hz, 1H, **H**₄), 8.30 (s, 1H, =**CH**–), 8.25 (dd, *J* = 7.8, 2.2 Hz, 1H, **H**₆), 8.06 (dd, *J* = 8.0, 1.2 Hz, 1H, **H**_{6'}), 7.59–7.52 (m, 1H, **H**_{3'}), 7.48 (t, *J* = 7.5 Hz, 1H, **H**_{5'}), 7.39 (t, *J* = 7.5 Hz, 1H, **H**_{4'}), 7.31 (d, *J* = 8.8 Hz, 1H, **H**₇), 3.72 (t, *J* = 2.4 Hz, 2H, –**CH**₂–CH₂–CH₃), 1.61 (m, 2H, –CH₂–**CH**₂–CH₃), 0.87 (t, *J* = 2.4 Hz, 3H, –CH₂–CH₂–**CH**₃) ppm.

¹³C-NMR (DMSO-*d*₆, 100 MHz) δ:

E-Diastereomer: 167.5, 149.4, 142.3, 136.1, 133.6, 132.7, 132.5, 130.9, 130.6, 128.1, 127.3, 127.2, 120.6, 117.9, 109.9, 41.9, 21, 11.6 ppm.

Z-Diastereomer: 165.6, 147.6, 142.9, 136.8, 134, 132.8, 132.2, 131.9, 129.6, 126.9, 126.6, 126.2, 123.8, 116.7, 109.2, 41.6, 21, 11.6 ppm.

Elemental analysis calculated/found for C₁₈H₁₅ClN₂O₃: C 63.07/62.89; H 4.41/4.58; N 8.17/8.45.

(*E/Z*)-3-(4-Fluorobenzylidene)-1-benzyl-indolin-2-one (7a). *E* : *Z* ratio = 18 : 82.

Yellow semisolid; yield: 67%;

¹H-NMR (DMSO-*d*₆, 400 MHz) δ:

Z-Diastereomer: 8.54 (dd, *J* = 8.5, 1.8 Hz, 2H, **H**_{2',6'}), 7.96 (s, 1H, =**CH**–), 7.79 (d, *J* = 8.5 Hz, 1H, **H**₄), 7.42–7.22 (m, 8H,

Benzylic Hs, **H**₅, **H**_{3',5'}, 7.06 (t, *J* = 8.7 Hz, 1H, **H**₆), 6.98 (d, *J* = 8.9 Hz, 1H, **H**₇), 5.00 (s, 2H, -**CH**₂-) ppm.

E-Diastereomer: 7.83 (dd, *J* = 8.5, 1.8 Hz, 2H, **H**_{2',6'}), 7.80 (s, 1H, =**CH**-), 7.56 (d, *J* = 8.5 Hz, 1H, **H**₄), 7.42–7.22 (m, 8H, Benzylic Hs, **H**₅, **H**_{3',5'}), 6.99 (d, *J* = 8.9 Hz, 1H, **H**₇), 6.92 (t, *J* = 8.7 Hz, 1H, **H**₆), 5.00 (s, 2H, -**CH**₂-) ppm.

¹³C-NMR (DMSO-d₆, 100 MHz) δ:

Z-Diastereomer: 165.7, 164.9, 162.4, 143.5, 136.5, 135.3, 132.4, 131.2, 130.6, 129.1 (2C), 127.9, 127.8 (2C), 125.4, 122.7, 122.3, 120.2, 116.5, 115.7, 109.5, 43.1 ppm.

E-Diastereomer: 167.8, 164.4, 161.9, 141.3, 137.2, 137, 135.2, 132.3, 129.4, 129.2 (2C), 127.9, 127.7 (2C), 126.9, 124.4, 122.4, 102.7, 116.3, 115.9, 110.1, 43 ppm.

Elemental analysis calculated/found for C₂₂H₁₆FNO: C 80.23/79.97; H 4.90/5.12; N 4.25/4.48.

(*E/Z*)-1-Propyl-3-(4'-fluorobenzylidene)-indolin-2-one (7b₁)

E : *Z* ratio = 2 : 98.

Yellow semisolid; yield: 55%;

¹H-NMR (DMSO-d₆, 400 MHz) δ:

Z-diastereomer: 8.51 (dd, *J* = 7.8, 1.8 Hz, 2H, **H**_{2',6'}), 7.89 (s, 1H, =**CH**-), 7.77 (d, *J* = 8.5 Hz, 1H, **H**₄), 7.36–7.26 (m, 3H, **H**_{3',5'}, **H**₆), 7.07 (m, 2H, **H**_{5,7}), 3.72 (t, 2H, -**CH**₂-**CH**₂-**CH**₃), 1.64 (m, 2H, -**CH**₂-**CH**₂-**CH**₃), 0.89 (t, 3H, -**CH**₂-**CH**₂-**CH**₃) ppm.

E-Diastereomer: 7.79 (dd, *J* = 7.8, 1.8 Hz, 2H, **H**_{2',6'}), 7.7 (s, 1H, =**CH**-), 7.54 (d, *J* = 8.5 Hz, 1H, **H**₄), 7.40–7.28 (m, 3H, **H**_{3',5'}, **H**₆), 7.11 (d, *J* = 8.8 Hz, 1H, **H**₇), 6.92 (t, *J* = 8.9 Hz, 1H, **H**₅), 3.72 (t, 2H, -**CH**₂-**CH**₂-**CH**₃), 1.64 (m, 2H, -**CH**₂-**CH**₂-**CH**₃), 0.89 (t, 3H, -**CH**₂-**CH**₂-**CH**₃) ppm.

¹³C-NMR (DMSO-d₆, 100 MHz) δ:

Z-Diastereomer: 167.6, 165.7, 162.3, 141.8, 136.4, 135.2, 135.1, 129.5, 125.7, 122.6, 122, 120.1, 115.8, 115.6, 109.1, 41.2, 21, 11.7 ppm.

E-Diastereomer: 164.8, 164.3, 161.8, 143.9, 135.9, 132.4, 132.3, 130.7, 127.1, 124.3, 122.1, 120.6, 116.5, 116.2, 109.6, 41.3, 20.9, 11.7 ppm.

Elemental analysis calculated/found for C₁₈H₁₆FNO: C 76.85/76.59; H 5.73/5.89; N 4.98/5.13.

(*E/Z*)-1-Propyl-3-(4'-fluorobenzylidene)-indolin-2-one (7b₂)

E : *Z* ratio = 88 : 12.

Yellow semisolid; yield: 55%; ¹H-NMR (DMSO-d₆, 400 MHz)

δ:

E-Diastereomer: 7.79 (dd, *J* = 7.8, 1.8 Hz, 2H, **H**_{2',6'}), 7.7 (s, 1H, =**CH**-), 7.54 (d, *J* = 8.5 Hz, 1H, **H**₄), 7.40–7.28 (m, 3H, **H**_{3',5'}, **H**₆), 7.11 (d, *J* = 8.8 Hz, 1H, **H**₇), 6.92 (t, *J* = 8.9 Hz, 1H, **H**₅), 3.71 (t, 2H, -**CH**₂-**CH**₂-**CH**₃), 1.64 (m, 2H, -**CH**₂-**CH**₂-**CH**₃), 0.90 (t, 3H, -**CH**₂-**CH**₂-**CH**₃) ppm.

Z-Diastereomer: 8.51 (dd, *J* = 7.8, 1.8 Hz, 2H, **H**_{2',6'}), 7.89 (s, 1H, =**CH**-), 7.77 (d, *J* = 8.5 Hz, 1H, **H**₄), 7.36–7.26 (m, 3H, **H**_{3',5'}, **H**₆), 7.07 (m, 2H, **H**_{5,7}), 3.69 (t, 2H, -**CH**₂-**CH**₂-**CH**₃), 1.64 (m, 2H, -**CH**₂-**CH**₂-**CH**₃), 0.89 (t, 3H, -**CH**₂-**CH**₂-**CH**₃) ppm.

¹³C-NMR (DMSO-d₆, 100 MHz) δ:

E-Diastereomer: 164.8, 164.3, 161.8, 143.9, 135.9, 132.4, 132.3, 130.7, 127.1, 124.3, 122.1, 120.6, 116.5, 116.2, 109.6, 41.3, 20.9, 11.7 ppm.

Z-Diastereomer: 167.6, 165.7, 162.3, 141.8, 136.4, 135.2, 135.1, 129.5, 125.7, 122.6, 122, 120.1, 115.8, 115.6, 109.1, 41.2, 21, 11.7 ppm.

Elemental analysis calculated/found for C₁₈H₁₆FNO: C 76.85/76.59; H 5.73/5.89; N 4.98/5.13.

Kinetic measurements

Isomerization rates of the tested compounds (**5a**, **5b**, **5c**₁, **5c**₂, **5d**, **6a**, **6c**, **7a**, **7b**₁, **7b**₂) in DMSO-d₆ were determined at room temperature. The reactions were initiated by dissolving 10 mg of the tested compound to 0.3 ml of DMSO-d₆ in NMR tubes. At appropriate intervals, the ¹H-NMR spectrum for each sample was measured, and the integral height values of the vinyl and 2',6'-protons chemical shifts of the respective *E* and *Z* diastereomers were determined. The residual heights displayed a first-order rate of kinetics. The results of the kinetic measurements are given in Tables 2 and 3.

Molecular modeling studies

The molecular docking studies were performed (Medicinal Chemistry Department, Faculty of Pharmacy, Assiut University, Egypt) using Molecular Operating Environment (MOE 2019.01, 2019; Chemical Computing Group, Canada) as the computational software. The three-dimensional structures and conformations of the enzyme, cyclin-dependent kinase enzyme (CDK2) in complex with sunitinib (PDB ID: 3TI1), was acquired from the Protein Data Bank (PDB) web site.⁴⁰ The binding affinity of the docked molecules was expressed as binding score (*S*, kcal mol⁻¹). Briefly, docking of the investigated molecules was performed in four steps: preparation of the 3D structure of the target, preparation of the ligands, running docking, and interpretation of the results. Docking was performed using the default settings of the MOE program [Placement, triangular Matcher; Rescoring 1, London dG with retain = 30; Refinement, Forcefield; Rescoring 2, GBVI/WSA dG with retain = 30]. The key amino acids involved in the interaction of sunitinib with CDK2 in the co-crystallized target are Ile10, Glu81, Leu83, Gln85 and Asp86. Re-docking of sunitinib was performed to accurately evaluate the efficiency of the method (rmsd = 2).

Conflicts of interest

The authors declare no conflict of interest.

References

- 1 M. Tutone and A. M. Almerico, *Eur. J. Med. Chem.*, 2017, **142**, 300–315.
- 2 H. N. Bramson, W. D. Holmes, R. N. Hunter, K. E. Lackey, B. Lovejoy, M. J. Luzzio, V. Montana, W. J. Rocque, D. Rusnak, L. Shewchuk, J. M. Veal, J. Corona, D. H. Walker, L. F. Kuyper, S. T. Davis, S. H. Dickerson, M. Edelstein, S. V. Frye, R. T. Gampe, P. A. Harris and A. Hassell, *J. Med. Chem.*, 2001, **44**, 4339–4358.
- 3 P. R. Murthi, N. Suresh, C. S. Rani, M. V. B. R. Rao and M. Pal, *Lett. Drug Des. Discovery*, 2015, **12**, 109–116.
- 4 J. Ai, M. Lv, X. Li, Z. Chen, G. Hu and Q. Li, *Med. Chem. Res.*, 2018, **27**, 161–170.

- 5 J. Zhang, P. L. Yang and N. S. Gray, *Nat. Rev. Cancer*, 2009, **9**, 28–39.
- 6 T. A. Chohan, A. Qayyum, K. Rehman, M. Tariq and M. S. H. Akash, *Biomed. Pharmacother.*, 2018, **107**, 1326–1341.
- 7 X. Grana and E. P. Reddy, *Oncogene*, 1995, **11**, 211–219.
- 8 U. Asghar, A. K. Witkiewicz, N. C. Turner and E. S. Knudsen, *Nat. Rev. Drug Discovery*, 2015, **14**, 130–146.
- 9 İ. Doğan, G. Bölek and B. Kahveci, *Synthesis of Some New Isatin Derivatives and Identification of Their Structures*, issue: Special [en] Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi, 2019, vol. 23, pp. 67–70, DOI: 10.19113/sdufenbed.432261.
- 10 N. E. A. A. El-sattar, E. H. K. Badawy, W. H. Abdel-hady, M. I. Abo-alkasem, A. A. Mandour and N. S. M. Ismail, *Chem. Pharm. Bull.*, 2021, **69**, 106–117.
- 11 P. Pakravan, S. Kashanian, M. M. Khodaei and F. J. Harding, *Pharmacol. Rep.*, 2013, **65**, 313–335.
- 12 G. M. Šekularac, J. B. Nikolić, P. Petrović, B. Bugarski, B. Durović and S. Z. Drmanić, *J. Serb. Chem. Soc.*, 2014, **79**, 1347–1354.
- 13 Y. Ding, L. Zhao, Y. Fu, L. Hao, Y. Fu, Y. Yuan, P. Yu and Y. Teng, *Molecules*, 2021, **26**, 176.
- 14 X. Chen, T. Yang, A. Deivasigamani, M. K. Shanmugam, K. M. Hui, G. Sethi and M. L. Go, *ChemMedChem*, 2015, **10**, 1548–1558.
- 15 T. T. L. Huong, D. T. M. Dung, N. Van Huan, L. Van Cuong, P. T. Hai, L. T. T. Huong, J. Kim, Y. G. Kim, S. B. Han and N. H. Nam, *Bioorg. Chem.*, 2017, **71**, 160–169.
- 16 D. T. M. Dung, P. T. P. Dung, D. T. K. Oanh, P. T. Hai, L. T. T. Huong, V. D. Loi, H. Hahn, B. W. Han, J. Kim, S.-B. Han and N.-H. Nam, *Med. Chem.*, 2015, **11**, 725–735.
- 17 W. Chu, D. Zhou, V. Gaba, J. Liu, S. Li, X. Peng, J. Xu, D. Dhavale, D. P. Bagchi, A. Avignon, N. B. Shakerdige, B. J. Bacskaï, Z. Tu, P. T. Kotzbauer and R. H. Mach, *J. Med. Chem.*, 2015, **58**, 6002–6017.
- 18 H. S. Al-Salem, M. Arifuzzaman, H. M. Alkahtani, A. N. Abdalla, I. S. Issa, A. Alqathama, F. S. Albalawi and A. F. M. Motiur Rahman, *Molecules*, 2020, **25**, 1–16.
- 19 L. Wollin, E. Wex, A. Pautsch, G. Schnapp, K. E. Hostettler, S. Stowasser and M. Kolb, *Eur. Respir. J.*, 2015, **45**, 1434–1445.
- 20 F. Dufrasne and M. Galanski, *Curr. Pharm. Des.*, 2007, **13**, 2781–2794.
- 21 K. Suman, Y. Bharath, V. Anuradha, V. Mandava and M. Pal, *Mini-Rev. Med. Chem.*, 2018, **18**, 1498–1505.
- 22 J. J. Haddad, *Saudi Pharm. J.*, 2012, **20**, 103–123.
- 23 R. Carbó-Dorca and P. Bultinck, *J. Math. Chem.*, 2004, **36**, 231–239.
- 24 K. I. Ramachandran, G. Deepa and K. Namboori, *Computational Chemistry and Molecular Modeling*, Springer, Berlin, Heidelberg, 2008.
- 25 T. H. Yang, C. I. Lee, W. H. Huang and A. R. Lee, *Molecules*, 2017, **22**, 1–19.
- 26 M. A. Yousef, A. M. Ali, W. M. El-Sayed, W. Saber, H. H. A. Farag and T. Aboul-Fadl, *Bioorg. Chem.*, 2020, **105**, 104366.
- 27 S. Varun and R. Kakkar, *MedChemComm*, 2019, **10**, 351–368.
- 28 W. J. Lin, K. S. Shia, J. S. Song, M. H. Wu and W. T. Li, *Org. Biomol. Chem.*, 2015, **14**, 220–228.
- 29 H. Cheng, X. Yao, S. Yin, T. Wang and Z. Zhang, *J. Org. Chem.*, 2020, **85**, 5863–5871.
- 30 C. Vila, S. Slack, G. Blay, M. C. Muñoz and J. R. Pedro, *Adv. Synth. Catal.*, 2019, **361**, 1902–1907.
- 31 S. Su, N. Wang, C. Li, B. Song, X. Jia and J. Li, *Asian J. Org. Chem.*, 2014, **3**, 269–272.
- 32 C. Crestini and R. Saladino, *Synth. Commun.*, 1994, **24**, 2835–2841.
- 33 S. Mokhtari, *Med. Chem.*, 2015, **5**, 242–252.
- 34 T. Kniess, M. Kuchar and F. Wuest, *Synth. Commun.*, 2008, **38**, 3017–3022.
- 35 R. P. Sonawane and R. R. Tripathi, *Int. Lett. Chem., Phys. Astron.*, 2013, **12**, 30–36.
- 36 C. Raji Reddy, V. Ganesh and A. K. Singh, *RSC Adv.*, 2020, **10**, 28630–28634.
- 37 H. Ankati, S. K. Akubathini, S. Kamila, C. Mukherjee, S. R. D. Mello and E. R. Biehl, *Open Org. Chem. J.*, 2009, **2**, 1–10.
- 38 F. J. D. Carlo, *J. Am. Chem. Soc.*, 1944, **66**, 1420.
- 39 K. R. Senwar, T. S. Reddy, D. Thummuri, P. Sharma, V. G. M. Naidu, G. Srinivasulu and N. Shankaraiah, *Eur. J. Med. Chem.*, 2016, **118**, 34–46.
- 40 <https://www.rscb.org/structure/3TI1>, accessed 6 October 2020.